ImmuCell Corporation
General ticker "ICCC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.4M (TTM average)
ImmuCell Corporation follows the US Stock Market performance with the rate: 30.9%.
Estimated limits based on current volatility of 3.4%: low 9.54$, high 10.21$
Factors to consider:
- Total employees count: 79 (+6.8%) as of 2023
- US accounted for 91.3% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Product liability, Supply chain disruptions, Regulatory and compliance
- Current price 21.3% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.73$, 8.29$]
- 2026-12-31 to 2027-12-31 estimated range: [5.05$, 8.78$]
Financial Metrics affecting the ICCC estimates:
- Negative: with PPE of -54.8 at the end of fiscal year the price was high
- Positive: -5.39 < Operating profit margin, % of 5.97
- Positive: -0.02 < Operating cash flow per share per price, % of 4.55
- Positive: -4.41 < Investing cash flow per share per price, % of -2.23
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 42.59 < Shareholder equity ratio, % of 63.61 <= 64.29
Short-term ICCC quotes
Long-term ICCC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $17.47MM | $26.49MM | $27.64MM |
| Operating Expenses | $23.22MM | $28.13MM | $25.99MM |
| Operating Income | $-5.75MM | $-1.64MM | $1.65MM |
| Non-Operating Income | $-0.02MM | $-0.51MM | $-2.68MM |
| R&D Expense | $4.39MM | $3.90MM | $3.04MM |
| Income(Loss) | $-5.77MM | $-2.15MM | $-1.03MM |
| Taxes | $0.00MM | $0.01MM | $0.01MM |
| Net Income(Loss)* | $-5.77MM | $-2.16MM | $-1.04MM |
| Stockholders Equity | $24.99MM | $27.52MM | $27.06MM |
| Inventory | $7.81MM | $7.11MM | $9.27MM |
| Assets | $43.81MM | $45.10MM | $42.53MM |
| Operating Cash Flow | $-4.67MM | $0.36MM | $2.48MM |
| Capital expenditure | $1.89MM | $0.47MM | $1.25MM |
| Investing Cash Flow | $-1.89MM | $-0.46MM | $-1.21MM |
| Financing Cash Flow | $1.75MM | $2.88MM | $-1.21MM |
| Earnings Per Share** | $-0.75 | $-0.26 | $-0.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.